UMB 425 is being called a breakthrough in the development of therapeutics to treat chronic pain, acts on two different opioid receptors with diminished tolerance over time and no obvious toxic effects.
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP), has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain. Spotlighted in a recent issue of ACS Chemical Neuroscience, the compound, known as UMB 425, is as strong as morphine, but displays diminished tolerance over time with no obvious toxic effects.
“UMB 425 is a breakthrough in the development of therapeutics to treat chronic pain,” says Coop. “Unlike other drugs developed to act on only one biological target, UMB 425 acts on two different opioid receptors in the body. When activated at the same time, these receptors work together to provide pain relief and slow the body’s development of tolerance to the drug. This diminished tolerance allows a lower dose of the opioid to be administered for a longer time period, while still achieving the same level of pain relief.”
For individuals living with chronic pain, either as a result of injury or disease such as arthritis, opioids are the standard treatment. But as the dosage increases to offset the body’s tolerance to their effects, opioids cause a number of adverse effects, including constipation, nausea, drowsiness, and dizziness. The unique dual-profile of UMB 425 – made possible through Coop’s collaborations with Alexander MacKerell, PhD, professor in PSC and director of the School’s Computer Aided Drug Design Center, and Maureen Kane, PhD, assistant professor in PSC and co-director of the School’s Mass Spectrometry Facility – provides both pain relief as well as diminished tolerance in one drug.
“Historically, medicinal chemists have developed drugs aimed at only one biological target,” says Coop. “However, two drugs administered together have the potential to metabolize differently in different individuals, as well as affect patients’ adherence to both drugs. A single compound that is able to provide both pain relief and diminished tolerance has the advantage of a defined ratio that we can optimize to ensure patients receive the maximum pain relief, while experiencing minimum adverse effects.”
Coop and his team conducted several in vitro and in vivo studies to determine the drug’s effectiveness in alleviating pain and diminishing tolerance over time. If future research and clinical trials are successful, UMB 425 could have a significant impact on the treatment and quality of life for individuals living with chronic pain.
“The clinical implication of this research has the potential to be tremendous,” says Mary Lynn McPherson, PharmD, BCPS, CPE, professor and vice chair for academic affairs in the Department of Pharmacy Practice and Science, and an international authority in the fields of pain management and palliative care. “If clinicians can prescribe lower doses of opioids, they will not have to raise a patient’s dose because of tolerance to the analgesic effects. Using lower doses will result in less severe adverse effects for the patient, both short-term effects such as nausea and constipation, as well as long-term adverse effects on the endocrine and immunologic systems. This would be a highly significant advance in pain management.”
The Latest Bing News on:
Chronic Pain
- Medtronic gets USFDA approval for Inceptiv closed-loop spinal cord stimulator for chronic painon April 27, 2024 at 4:28 am
Dublin: Medtronic plc, a global leader in healthcare technology, has announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv closed-loop rechargeable spinal ...
- A Predictive Healthcare Visionary Is Optimistic About Solving America’s Opioid Addiction And Chronic Pain Epidemicon April 26, 2024 at 2:20 pm
Studies found that Chronic pain is more prevalent and costly than cancer, diabetes, and heart disease combined, and its rates are rising even as other chronic ...
- Scientists Make Breakthrough in Chronic Pain Treatmenton April 26, 2024 at 7:53 am
Scientists have developed tiny robotic nerve "cuffs" to diagnose and treat neurological disorders. The flexible devices offer a safer, minimally invasive alternative to today's diagnostics and could ...
- Medtronic wins FDA approval for adjustable spine-pain implanton April 26, 2024 at 5:05 am
Medtronic said that the FDA approved its new spinal implant, which delivers a variable electrical pulse to interrupt pain signals before they reach the brain.
- New Research Links Chronic Pain to Socioeconomic Backgroundon April 25, 2024 at 9:53 pm
New research indicates that the development of chronic musculoskeletal pain may be influenced by factors such as socioeconomic status, fear of movement, smoking, and weaker support networks. In a ...
- FDA Clears Inceptiv, a Closed-Loop Spinal Cord Stimulator for Chronic Painon April 25, 2024 at 5:00 pm
The Food and Drug Administration (FDA) has approved the Inceptiv ™ closed-loop rechargeable spinal cord stimulator (SCS) as an aid in the management of chronic, intractable pain of the trunk and/or ...
- Chronic pain linked to socioeconomic backgroundon April 25, 2024 at 6:08 am
People with a lower socioeconomic background were twice as likely to develop chronic pain following injury, a new study has found.
- From a Kansan with chronic pain: It’s time for our state to embrace medical cannabison April 25, 2024 at 1:33 am
I started feeling sluggish. I felt like I had a fever, even though my temperature never topped 100 degrees. The pain in your skin when you’re feverish, the ache you feel in your joints. I felt ...
- Neuroscientists report a distinct role of touch receptors in treating chronic painon April 23, 2024 at 7:01 am
People often experience the phenomenon of injuring a hand and feeling relief from vigorously shaking it. The mechanism behind this effect is fairly well explained by the "gate control theory" of ...
- Depression linked to chronic pain: Variability shown across patient characteristicson April 23, 2024 at 5:31 am
Chronic pain is a major global disability cause, affecting over 30% of the population and often coexisting with depression, which disables roughly 5% of adults worldwide. The relationship between ...
The Latest Google Headlines on:
Chronic Pain
[google_news title=”” keyword=”Chronic Pain” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
UMB 425
- UMB Financial Corporation (UMBF)on April 25, 2024 at 9:00 am
Do the numbers hold clues to what lies ahead for the stock? Key Insights UMB Financial will host its Annual General Meeting on 30th of April CEO J. Kemper's total compensation... KANSAS CITY ...
- UMB Financial Corp UMBFon April 22, 2024 at 4:59 pm
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
- UMB Financialon April 18, 2024 at 5:00 pm
UMB Financial Corporation is a financial services company headquartered in Kansas City, Missouri. UMB offers commercial banking, which includes comprehensive deposit, lending and investment ...
- UMB Financial (UMBF) Rides on Loan Growth Amid Rising Costson April 4, 2024 at 10:36 am
UMB Financial Corporation UMBF benefits from balance-sheet strength on the back of increasing loan and deposit balances. Given the decent liquidity position, the company’s capital distribution ...
- We are on track to recapitalize before 2025 deadline -UMBon April 1, 2024 at 8:52 am
Universal Merchant Bank (UMB) has assured the public and customers that it is on track to recapitalize to the new levels before the 2025 deadline set by the Bank of Ghana. This was contained in a ...
- UMB acknowledges appointment of advisor for recapitalization effortson March 28, 2024 at 5:00 pm
The Board of Universal Merchant Bank Ltd (UMB) hereby acknowledges the appointment of Dr. Joseph France as an Advisor to support the Bank in its recapitalization drive as contained in Bank of ...
- Ex-Dividend Reminder: UMB Financial, Old Republic International and Healthstreamon March 6, 2024 at 6:57 am
Looking at the universe of stocks we cover at Dividend Channel, on 3/8/24, UMB Financial Corp (Symbol: UMBF), Old Republic International Corp. (Symbol: ORI), and Healthstream Inc (Symbol ...
- UMBF UMB Financial Corporationon March 2, 2024 at 7:23 pm
UMB Financial Corporation operates as the bank holding company that provides banking services and asset servicing in the United States and internationally. The Commercial Banking segment provides ...
- S&P just downgraded some big banks. Here are the 5 that are impacted.on August 21, 2023 at 5:00 pm
Green Bay, Wisconsin-based Associated Banc Corp. ranks No. 49, with $41 billion, followed by Kansas City, Missouri-based UMB, which is ranked No. 50, also with $41 billion. Valley National ...
- UMB Financial Corp.on March 14, 2023 at 9:02 am
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Latest Google Headlines on:
UMB 425
[google_news title=”” keyword=”UMB 425″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]